PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: A meta-analysis

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Wu, Jiaying ^a   Hong, Dongsheng ^a   Zhang, Xiangnan ^b   Lu, Xiaoyang ^a   Miao, Jing ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DOSE RESPONSE; FEMALE; HUMAN; INCIDENCE; KIDNEY TUMOR; LUNG TUMOR; MALE; META ANALYSIS; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RENAL CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; PNEUMONIA; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85014963217     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep44173     Document Type: Article

References (52)

1. Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T. & Honjo, T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 98, 13866-13871, doi: 10.1073/pnas.231486598 (2001).
2. Okazaki, T. & Honjo, T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 27, 195-201, doi: 10.1016/j. it.2006.02.001 (2006).
3. Nishimura, H. & Honjo, T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 22, 265-268, doi: S1471-4906(01)01888-9 [pii] (2001).
4. Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26, 677-704, doi: 10.1146/annurev.immunol.26.021607.090331 (2008).
5. Hirano, F. et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65, 1089-1096, doi: 65/3/1089 [pii] (2005).
6. Topalian, S. L., Drake, C. G. & Pardoll, D. M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24, 207-212, doi: 10.1016/j.coi.2011.12.009 (2012).
7. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571, doi: 10.1038/ nature13954 (2014).
8. Barbee, M. S., Ogunniyi, A., Horvat, T. Z. & Dang, T. O. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 49, 907-937, doi: 10.1177/1060028015586218 (2015).
9. Weber, J. S. et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 17, 943-955, doi: 10.1016/S1470-2045(16)30126-7 (2016).
10. Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372, 2006-2017, doi: 10.1056/NEJMoa1414428 (2015).
11. Larkin, J. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373, 23-34, doi: 10.1056/NEJMoa1504030 (2015).
12. Postow, M. A. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 76-83, doi: 10.14694/ EdBook-AM.2015.35.76 (2015).
13. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366, 2443-2454, doi: 10.1056/NEJMoa1200690 (2012).
14. Naidoo, J. et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26, 2375-2391, doi: 10.1093/ annonc/mdv383 (2015).
15. Friedman, C. F., Proverbs-Singh, T. A. & Postow, M. A. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol, doi: 10.1001/jamaoncol.2016.1051 (2016).
16. Moher, D., Liberati, A., Tetzlaf, J., Altman, D. G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535, doi: 10.1136/bmj.b2535 (2009).
17. US National Institutes of Health, B., MD. CommonTerminology for Clinical Adverse Events Version 4.03. Respiratory, thoracic and mediastinal disorders June 14, 2010. http://evs.nci.nih.gov/fp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf Accessed February 06, 2013.
18. Jadad, A. R. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17, 1-12, doi: 0197-2456(95)00134-4 [pii] (1996).
19. Sweeting, M. J., Sutton, A. J. & Lambert, P. C. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in medicine 23, 1351-1375, doi: 10.1002/sim.1761 (2004).
20. Brahmer, J. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373, 123-135, doi: 10.1056/NEJMoa1504627 (2015).
21. Ribas, A. et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16, 908-918, doi: 10.1016/S1470-2045(15)00083-2 (2015).
22. Le, D. T. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372, 2509-2520, doi: 10.1056/ NEJMoa1500596 (2015).
23. Robert, C. et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372, 2521-2532, doi: 10.1056/ NEJMoa1503093 (2015).
24. Motzer, R. J. et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 33, 1430-1437, doi: 10.1200/JCO.2014.59.0703 (2015).
25. Rizvi, N. A. et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16, 257-265, doi: 10.1016/S1470-2045(15)70054-9 (2015).
26. Borghaei, H. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 373, 1627-1639, doi: 10.1056/NEJMoa1507643 (2015).
27. Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16, 375-384, doi: 10.1016/S1470-2045(15)70076-8 (2015).
28. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372, 320-330, doi: 10.1056/ NEJMoa1412082 (2015).
29. Motzer, R. J. et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373, 1803-1813, doi: 10.1056/ NEJMoa1510665 (2015).
30. Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540-1550, doi: 10.1016/S0140-6736(15)01281-7 (2016).
31. Nghiem, P. T. et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med 374, 2542-2552, doi: 10.1056/NEJMoa1603702 (2016).
32. Kojima, T. et al. Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: Preliminary report of overall survival. Journal of Clinical Oncology 34 (2016).
33. Hamanishi, J. et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol 33, 4015-4022, doi: 10.1200/JCO.2015.62.3397 (2015).
34. Younes, A. et al. Nivolumab for classical Hodgkin's lymphoma afer failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17, 1283-1294, doi: 10.1016/S1470-2045(16)30167-X (2016).
35. Nishino, M. et al. Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. Cancer Immunol Res 4, 289-293, doi: 10.1158/2326-6066.CIR-15-0267 (2016).
36. Nishino, M., Sholl, L. M., Hodi, F. S., Hatabu, H. & Ramaiya, N. H. Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med 373, 288-290, doi: 10.1056/NEJMc1505197 (2015).
37. Spain, L., Diem, S. & Larkin, J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44, 51-60, doi: 10.1016/j.ctrv.2016.02.001 (2016).
38. Kwok, G., Yau, T. C., Chiu, J. W., Tse, E. & Kwong, Y. L. Pembrolizumab (Keytruda). Hum Vaccin Immunother 0, doi: 10.1080/21645515.2016.1199310 (2016).
39. Carroll, J. Anti-PD-1? Well, no, says Medivation as a partial hold forces a halt to 'pivotal' cancer study (2016).
40. Villadolid, J. & Amin, A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 4, 560-575, doi: 10.3978/j.issn.2218-6751.2015.06.06 (2015).
41. Nishino, M., Ramaiya, N. H., Hatabu, H., Hodi, F. S. & Armand, P. F. PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy. British journal of haematology, doi: 10.1111/bjh.14441 (2016).
42. Wolchok, J. D. et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11, 155-164, doi: 10.1016/S1470-2045(09)70334-1 (2010).
43. Maker, A. V. et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29, 455-463, doi: 10.1097/01.cji.0000208259.73167.58 (2006).
44. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28, 3167-3175, doi: 10.1200/JCO.2009.26.7609 (2010).
45. Prokunina, L. et al. Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis and rheumatism 50, 1770-1773, doi: 10.1002/art.20280 (2004).
46. Kong, E. K. et al. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis and rheumatism 52, 1058-1062, doi: 10.1002/art.20966 (2005).
47. Adegunsoye, A. et al. Predictors of survival in coexistent hypersensitivity pneumonitis with autoimmune features. Respiratory medicine 114, 53-60, doi: 10.1016/j.rmed.2016.03.012 (2016).
48. Strek, M. E. & Costabel, U. Interstitial pneumonia with autoimmune features: a critical appraisal of the new defnition. Current opinion in pulmonary medicine 22, 442-449, doi: 10.1097/MCP.0000000000000298 (2016).
49. Wakasa-Morimoto, C. et al. Arthritis and pneumonitis produced by the same T cell clones from mice with spontaneous autoimmune arthritis. International immunology 20, 1331-1342, doi: 10.1093/intimm/dxn091 (2008).
50. Rojas, C. M. et al. Bronchiolitis obliterans organizing pneumonia in patients with autoimmune rheumatic diseases. Immunologic research 61, 97-103, doi: 10.1007/s12026-014-8607-z (2015).
51. Chow, L. Q. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. Am Soc Clin Oncol Educ Book, doi: 10.1200/EdBook-AM.2013.33.e280 (2013).
52. Michot, J. M. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54, 139-148, doi: 10.1016/j.ejca.2015.11.016 (2016).